Motus GI Holdings Inc (NASDAQ:MOTS) was the recipient of a significant decline in short interest in September. As of September 15th, there was short interest totalling 428,900 shares, a decline of 10.1% from the August 31st total of 476,900 shares. Based on an average daily volume of 86,700 shares, the short-interest ratio is currently 4.9 days. Approximately 1.6% of the company’s stock are short sold.
Shares of Motus GI stock traded up $0.01 on Friday, reaching $0.96. The stock had a trading volume of 116,225 shares, compared to its average volume of 120,024. The business’s 50-day moving average price is $1.02 and its two-hundred day moving average price is $1.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.77 and a current ratio of 1.90. Motus GI has a fifty-two week low of $0.46 and a fifty-two week high of $2.85. The stock has a market cap of $27.91 million, a P/E ratio of -1.27 and a beta of 2.78.
Motus GI (NASDAQ:MOTS) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.06. Motus GI had a negative net margin of 16,834.35% and a negative return on equity of 139.08%. As a group, equities analysts forecast that Motus GI will post -0.62 earnings per share for the current fiscal year.
Several research firms have commented on MOTS. Zacks Investment Research downgraded shares of Motus GI from a “buy” rating to a “hold” rating in a research report on Tuesday, August 18th. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Motus GI in a research report on Tuesday, June 16th. Oppenheimer reissued a “buy” rating and issued a $2.50 target price on shares of Motus GI in a research report on Wednesday, August 12th. Colliers Secur. reissued a “buy” rating on shares of Motus GI in a research report on Wednesday, August 12th. Finally, Alliance Global Partners boosted their target price on shares of Motus GI from $1.65 to $2.60 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $2.47.
Motus GI Company Profile
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Featured Story: What is an economic bubble?
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.